<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Healthcare on FinanClub</title>
    <link>https://finan.club/tags/healthcare/</link>
    <description>Recent content in Healthcare on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 26 Jan 2024 09:05:43 +0000</lastBuildDate><atom:link href="https://finan.club/tags/healthcare/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Fri, 26 Jan 2024 09:05:43 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:174
Chances: Merck &amp;amp; Co., Inc. is engaged in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care productsThe company operates in Pharmaceutical, Animal Health, and Other segmentsIt has entered into a clinical trial collaboration agreement with LAVA Therapeutics NV for evaluation of its anti-PD-1 therapy Keytruda Risks: The company&amp;rsquo;s stock price might be vulnerable to the large stake held by institutionsUncertainty around the future of stock markets remains highThe Senate HELP committee is seeking testimony from the company Score:174 chances characters count - risks characters count = 174</description>
    </item>
    
    <item>
      <title>ABT</title>
      <link>https://finan.club/us/abt/</link>
      <pubDate>Thu, 25 Jan 2024 09:07:34 +0000</pubDate>
      
      <guid>https://finan.club/us/abt/</guid>
      <description>score:20
Chances: Abbott Laboratories has shown strong sales growth in its medical devices segment, offsetting declines in COVID-19 testing revenue.The company&amp;rsquo;s performance in the fourth quarter of 2023 was in line with expectations and even beat sales estimates.The healthcare industry is a rapidly developing sector, and Abbott&amp;rsquo;s diverse line of healthcare products positions it well for continued growth.</description>
    </item>
    
    <item>
      <title>JNJ</title>
      <link>https://finan.club/us/jnj/</link>
      <pubDate>Wed, 24 Jan 2024 09:08:15 +0000</pubDate>
      
      <guid>https://finan.club/us/jnj/</guid>
      <description>score:51
Chances: Johnson &amp;amp; Johnson beat fourth-quarter expectations with strong performance in the medtech segment. The company reported adjusted earnings of $2.29 per share, up 11.7% year-over-year, beating the consensus. Sales increased by 7.3% year-over-year to $21.4 billion, surpassing the consensus. Risks: Johnson &amp;amp; Johnson&amp;rsquo;s stock tumbled after the company reported lower profit margins in the medical device and technology unit last quarter.</description>
    </item>
    
    <item>
      <title>KVUE</title>
      <link>https://finan.club/us/kvue/</link>
      <pubDate>Fri, 12 Jan 2024 09:06:15 +0000</pubDate>
      
      <guid>https://finan.club/us/kvue/</guid>
      <description>score:39
Chances: Kenvue Inc. is poised to benefit from the favorable court ruling in a product-liability case, which has resulted in a nearly 5% increase in the company&amp;rsquo;s stock price. The Self Care segment, including cough, cold and allergy, pain care, digestive health, and smoking cessation, presents a strong opportunity for growth and revenue generation.</description>
    </item>
    
    <item>
      <title>GDRX</title>
      <link>https://finan.club/us/gdrx/</link>
      <pubDate>Thu, 11 Jan 2024 09:04:35 +0000</pubDate>
      
      <guid>https://finan.club/us/gdrx/</guid>
      <description>score:82
Chances: Shares of GoodRx (GDRX) popped after reporting upbeat preliminary fourth quarter and full year 2023 results. GoodRx unveiled preliminary fourth-quarter revenue that topped analysts&amp;rsquo; estimates. The company has seen &amp;ldquo;great demand&amp;rdquo; for its products, indicating potential growth opportunities. Risks: The company operates in the highly competitive healthcare industry.</description>
    </item>
    
    <item>
      <title>CLVT</title>
      <link>https://finan.club/us/clvt/</link>
      <pubDate>Tue, 09 Jan 2024 09:07:33 +0000</pubDate>
      
      <guid>https://finan.club/us/clvt/</guid>
      <description>score:-7
Chances: Clarivate Plc has been consistently releasing new reports and products, indicating a strong focus on innovation and meeting the evolving needs of the healthcare and research industries. Risks: The company operates in a highly competitive market, and its success depends on the adoption of its products and solutions by academia, government, life sciences, and healthcare organizations.</description>
    </item>
    
    <item>
      <title>HIMS</title>
      <link>https://finan.club/us/hims/</link>
      <pubDate>Wed, 03 Jan 2024 09:07:26 +0000</pubDate>
      
      <guid>https://finan.club/us/hims/</guid>
      <description>score:108
Chances: Hims &amp;amp; Hers Health, Inc. unveiled Weight Loss by Hims &amp;amp; Hers, a comprehensive and customizable clinical approach specifically designed to help people achieve their individual weight-loss goals. The company has appointed Craig Primack, a pioneer in the field of clinical obesity medicine, as SVP of Weight Management, indicating a strong focus on addressing the growing issue of obesity.</description>
    </item>
    
    <item>
      <title>OGN</title>
      <link>https://finan.club/us/ogn/</link>
      <pubDate>Wed, 20 Dec 2023 09:03:44 +0000</pubDate>
      
      <guid>https://finan.club/us/ogn/</guid>
      <description>score:21
Chances: Organon&amp;rsquo;s partnership with Sempre Health to improve medication adherence shows a proactive approach to patient care and may lead to increased sales. The company&amp;rsquo;s exclusive distribution of Emgality and RAYVOW in Europe presents a significant opportunity for revenue growth in the region.</description>
    </item>
    
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 19 Dec 2023 09:06:54 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-135
Chances: AstraZeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. The additional supply of RSV shot for infants by AstraZeneca and Sanofi indicates a positive outlook for meeting winter demand.</description>
    </item>
    
  </channel>
</rss>
